The Future-Proof Her Business Summit Offers Tech-Savvy Strategies for Women Entrepreneurs
Top Experts Share Real Strategies for Business Growth without the Overwhelm
Colorado - July 17, 2025 - Founder & CEO of GeekPack®, Julia Taylor, is pleased to announce The Future-Proof Her Business Summit, July 21-23, a free three-day virtual event designed to help women entrepreneurs navigate AI overwhelm, uncertainty, and create a roadmap for smart business growth. Participants will learn from experts in mindset, AI, and business growth in a series of short yet informative sessions.
The Future-Proof Her Business Summit is designed to help women business owners adapt, grow, and stay relevant during these fast-changing times. Whether you're a solopreneur or heading a small team, these sessions will give you strategies to help navigate change with confidence.
The Future-Proof Her Business Summit features an array of engaging guest speakers, including:
Julie Chenell (Marketing & Business)
Helen Henley (Mindset)
Brittany Long (Impact-Driven AI)
LaToya Russell (Automations)
Christine LaVopa (Health & Fitness)
experts from Relay (Cash Flow)
real business owners
and host Julia Taylor, the CEO and Founder of GeekPack
What makes this summit so unique?
Intentional Schedule & Structured Flow - Thoughtfully paced sessions ensure participants feel engaged but never overloaded
High-Value Expert Sessions & Interactive Chats - No fluff sessions from experts focusing on actionable insights and strategies that can be implemented right away
Built-In Reflection & Networking Time - Connecting with fellow business owners to build meaningful connections, personalized support, and daily prompts to anchor in the trainings
Actionable, Manageable Steps - Walk away each day feeling more confident, armed with practical next-steps that can be easily integrated into your business
By the end of the Summit, participants will have a clear roadmap of how to grow their business with ease; a fresh perspective on how to integrate AI tools into their operations to save time and money; a sense of empowerment that anything is possible; and a community that is there to support, and uplift women who are making the world a better place through business.
'I created these events after seeing so many entrepreneurs spinning their wheels, feeling overwhelmed, and unsure how to navigate rapid AI changes,' states Julia Taylor, Founder & CEO of GeekPack. 'This summit is about giving women a renewed sense of confidence, clarity, and a tangible plan to grow their businesses without burning out.'
'Starting a small business takes grit and ambition, but keeping it going means always having your eye on the money,' says Yoseph West, Co-Founder & CEO of Relay. 'At Relay, every move we make is about enabling anyone to build a long-lasting and profitable business. Partnering with GeekPack is an obvious match. They support a vibrant community of dedicated entrepreneurs focused on building their long-term futures. Together, we're not just simplifying financial management, we're sparking sustainable growth for business owners everywhere."
The Future-Proof Her Business Summit is a free, virtual summit running July 21-23, 2025. Each day features sessions with subject matter experts and daily action steps to create business momentum. Participants will walk away with practical strategies, cutting-edge tools, and a clear road map of what to do next for their business. Proudly sponsored by Relay, Verizon Small Business Digital Ready, and our Community Network Partners.
Free registration is available at: https://geekpack.com/july-summit
About GeekPack
Since 2018, GeekPack has been transforming the lives of women by equipping them with the skills, strategies, and support to confidently build businesses that thrive in a digital world. With a flourishing community reaching over 162,000 aspiring and growing entrepreneurs, GeekPack's engaging events and programs provide valuable expertise for building successful, future-ready businesses. Founder Julia Taylor's impact has been recognized by the Tory Burch Foundation and the Cartier Women's Initiative, where she was honored as a 2024 Fellow.
Learn more at https://geekpack.com
About Relay
Relay is an online banking platform that puts business owners in complete control of their cash flow. By helping them clearly understand what they're earning, spending, and saving, Relay empowers entrepreneurs to make smarter decisions about their business and reach peak profitability.
Disclaimer: Relay is a financial technology company, not a bank. Banking services are provided by Thread Bank; Member FDIC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why BigBear.ai Stock Skyrocketed Last Week
Key Points stock surged 23.5% over the past week despite no major news for the business. The company's share price has continued to climb thanks to excitement surrounding defense-AI investments. explosive valuation has seen explosive gains lately despite little indication the company's outlook has seen big shifts. 10 stocks we like better than › (NYSE: BBAI) stock closed out this past week's trading with another run of big gains. The software and services company's share price climbed 23.5% from the previous week's market close amid a gain of 0.6% for the S&P 500 index. valuation surged again this past week, as investors continued to place bullish bets on companies with artificial intelligence (AI) tools tailored for the defense industry. The company's share price is now up 101% over the past month and 214% over the past three months. stock continues to surge despite no major news Even in the absence of apparent meaningful developments for the business, stock has continued to rally. The company's big valuation gains appear to be primarily connected to the defense-AI investment trend that has been hot in the market. Palantir has been a top defense-AI play and reached a new valuation high in this week's trading, and stock has often seen valuation moves that correspond with pricing action for the software leader. Some investors are betting that could emerge as a Palantir-like winner as demand for AI-powered defense software continues to increase. What's next for The massive valuation run up for stock appears to be out of step with the company's recent business performance and near-term outlook. Despite demand tailwinds in the AI industry, the company's revenue increased just 5% year over year in the last quarter. Growth is expected to accelerate in the second half of the company's current fiscal year, but management's midpoint target for annual sales growth of roughly 7.5% still raises valuation concerns following recent gains for the stock. While it's possible that continued acceleration for sales growth and margin improvements will pave the way for stock to see more explosive gains above its current valuation level, huge valuation gains in the absence of major news suggest that the company is a risky investment right now. Investors will get a closer look at the business on Aug. 11, when the company publishes its next quarterly report. Should you invest $1,000 in right now? Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
2 hours ago
- Globe and Mail
Imagen Network (IMAGE) Enhances Social Customization with Grok AI Real-Time Processing Engines
New integration enables intelligent, adaptive content delivery and live personalization across decentralized social feeds. London, United Kingdom--(Newsfile Corp. - July 21, 2025) - Imagen Network, the decentralized AI social platform, has expanded its personalization infrastructure by embedding real-time processing engines powered by Grok AI. This enhancement delivers live content curation, emotion-aware feed structuring, and interactive customization for users across Ethereum, BNB Chain, and Solana. Delivering real-time AI customization for smarter, adaptive social interaction. To view an enhanced version of this graphic, please visit: The new processing layer enables Imagen to analyze behavior, engagement context, and sentiment cues in real time-allowing AI-generated suggestions, moderation tools, and creator recommendations to adapt fluidly to user preferences. Unlike static content systems, this engine ensures that every feed, profile, and post is dynamically tailored to its environment and audience. Grok AI's integration supports Imagen's modular social nodes by allowing communities to define their own personalization logic while benefiting from high-speed processing and contextual relevance. Whether delivering curated discussions, AI-enhanced visuals, or governance prompts, every element can now be tuned to individual and community identity. Imagen's real-time AI layer represents a leap in decentralized expressiveness-ensuring that social interaction is not only user-owned, but intelligent, responsive, and optimized for scale. About Imagen Network Imagen Network is a decentralized social platform that blends AI content generation with blockchain infrastructure to give users creative control and data ownership. Through tools like adaptive filters and tokenized engagement, Imagen fosters a new paradigm of secure, expressive, and community-driven networking. Media Contact Dorothy Marley KaJ Labs +1 707-622-6168 media@ Social Media Twitter Instagram
Globe and Mail
3 hours ago
- Globe and Mail
3 Monster Stocks in the Making to Buy Right Now
Key Points CRISPR Therapeutics is still in its early growth stage. Summit Therapeutics has plenty of upside potential remaining. Viking Therapeutics is targeting two monster markets. 10 stocks we like better than CRISPR Therapeutics › Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings. Three Motley Fool contributors think they've identified monster stocks in the making. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX). Image source: Getty Images. A promising company in its early growth stage David Jagielski (CRISPR Therapeutics): Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable in the long run. The gene editing market is still fairly small, but it has a lot of room to grow. Analysts from Grand View Research project that it will expand at a compound annual growth rate of more than 16% between now and 2030, when it will be worth $25 billion. As a leading company in the space, CRISPR Therapeutics is well positioned to benefit from future growth in this area of healthcare. The company, and its key development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), already have an approved gene therapy treatment in Casgevy, which regulators have approved for both sickle cell disease and transfusion-dependent beta-thalassemia. The companies will share in the profits on the treatment (CRISPR will take 40%). Casgevy is still in its early growth stages. CRISPR is also working on developing treatments for type 1 diabetes and cardiovascular disease. While CRISPR remains unprofitable today, its future does look bright. It's a long road ahead for CRISPR Therapeutics, but with an encouraging pipeline and a lot of growth potential, this could be a monster healthcare stock in the making. The business is well funded with its cash and marketable securities as of the end of March totaling nearly $1.9 billion, putting it in an excellent position to continue investing in its research and development efforts. CRISPR can make for an excellent investment, but it's also one you'll need to be patient with. Still plenty of upside left for this stock Prosper Junior Bakiny (Summit Therapeutics): Few biotech companies have performed better than Summit Therapeutics over the past three years. The company's shares have soared by more than 2,000%, making early investors who held on significantly wealthier in the process. Here's the good news for those who are still considering the stock: There could be a massive upside left for Summit Therapeutics. Though the biotech generates no revenue and is unprofitable, it has one of the more promising pipeline products in the industry. Summit Therapeutics' leading candidate is a cancer medicine called ivonescimab, which it licensed out from Akeso Biopharma (OTC: AKES.F), a China-based drug developer. The medicine has been extensively tested in China, where it has already received approval in certain indications. One of ivonescimab's most promising markets is non-small cell lung cancer (NSCLC). In a phase 3 study in China, it went head-to-head against the market leader and the world's best-selling drug: Merck 's (NYSE: MRK) Keytruda. Ivonescimab emerged victorious, leading to a greater decrease in the risk of recurrence or death among NSCLC patients with a PD-L1 protein overexpression. Summit Therapeutics is conducting clinical studies to support approval in the U.S. and other regions. Furthermore, the biotech is likely to seek a series of approvals and label expansions over the years, based on the number of clinical trials and indications Akeso is targeting in China. Ivonescimab should easily become a blockbuster and generate strong sales for years. That's why it's not too late to invest in Summit Therapeutics. If ivonescimab achieves its full potential, Summit could deliver market-beating returns in the next five to 10 years and establish itself as a prominent player in the biotech industry. Targeting two monster markets Keith Speights (Viking Therapeutics): The big story for Viking Therapeutics is its experimental obesity drug VK2735. The company recently advanced a subcutaneous formulation of this candidate into late-stage clinical testing after announcing highly encouraging results from a phase 2 study last year. Viking is also evaluating an oral version of VK2735 in a separate phase 2 clinical trial, and it expects to report results from that study later in 2025. In addition, the drugmaker plans to initiate a clinical study for a monthly maintenance version of subcutaneous VK2735 in the coming months. Morgan Stanley Research projects that the global obesity drug market could reach $150 billion by 2035. Viking could be in a great position to claim a nice chunk of that market if VK2735 fulfills its potential. Obesity isn't the only big market that the company is targeting, though. In 2023, Viking reported positive results from a phase 2 study of VK2809 in treating metabolic-associated steatohepatitis (MASH), a chronic liver disease also known as nonalcoholic steatohepatitis (NASH). The company is seeking a partner to advance VK2809 into late-stage testing, so it can dedicate its financial resources exclusively to VK2735 for now. Grand View Research predicts the MASH/NASH market could hit $33.8 billion by 2030, so that's a nice opportunity. A clinical trial flop for VK2735 and/or a failure to find a partner for VK2809 could prevent Viking from becoming a monster stock. However, I think the company's chances look pretty good. I also wouldn't be surprised if a larger drugmaker swoops in to acquire Viking. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
